Cargando…

A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease

BACKGROUND: Movement disorders in Huntington’s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojtecki, Lars, Groiss, Stefan J., Ferrea, Stefano, Elben, Saskia, Hartmann, Christian J., Dunnett, Stephen B., Rosser, Anne, Saft, Carsten, Südmeyer, Martin, Ohmann, Christian, Schnitzler, Alfons, Vesper, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539552/
https://www.ncbi.nlm.nih.gov/pubmed/26347707
http://dx.doi.org/10.3389/fneur.2015.00177
_version_ 1782386128154787840
author Wojtecki, Lars
Groiss, Stefan J.
Ferrea, Stefano
Elben, Saskia
Hartmann, Christian J.
Dunnett, Stephen B.
Rosser, Anne
Saft, Carsten
Südmeyer, Martin
Ohmann, Christian
Schnitzler, Alfons
Vesper, Jan
author_facet Wojtecki, Lars
Groiss, Stefan J.
Ferrea, Stefano
Elben, Saskia
Hartmann, Christian J.
Dunnett, Stephen B.
Rosser, Anne
Saft, Carsten
Südmeyer, Martin
Ohmann, Christian
Schnitzler, Alfons
Vesper, Jan
author_sort Wojtecki, Lars
collection PubMed
description BACKGROUND: Movement disorders in Huntington’s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. METHODS: In a controlled double-blind phase six patients (four chorea-dominant, two Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6-week internal- or 6-week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington’s Disease Rating Scale motor-score, chorea subscore, and total motor-score 4 (blinded-video ratings), comparing internal- versus external-pallidal stimulation, and 6 months versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability, and quality-of-life. RESULTS: Intention-to-treat analysis of all patients (n = 3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (−5.3 (60.2%), p = 0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. Eight adverse events and two additional serious adverse events – mostly internal-pallidal stimulation-related – resolved without sequalae. No procedure-related complications occurred. CONCLUSION: Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington’s disease. Their effects on chorea and dystonia and on quality-of-life should be examined in larger controlled trials.
format Online
Article
Text
id pubmed-4539552
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45395522015-09-07 A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease Wojtecki, Lars Groiss, Stefan J. Ferrea, Stefano Elben, Saskia Hartmann, Christian J. Dunnett, Stephen B. Rosser, Anne Saft, Carsten Südmeyer, Martin Ohmann, Christian Schnitzler, Alfons Vesper, Jan Front Neurol Neuroscience BACKGROUND: Movement disorders in Huntington’s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. METHODS: In a controlled double-blind phase six patients (four chorea-dominant, two Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6-week internal- or 6-week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington’s Disease Rating Scale motor-score, chorea subscore, and total motor-score 4 (blinded-video ratings), comparing internal- versus external-pallidal stimulation, and 6 months versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability, and quality-of-life. RESULTS: Intention-to-treat analysis of all patients (n = 3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (−5.3 (60.2%), p = 0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. Eight adverse events and two additional serious adverse events – mostly internal-pallidal stimulation-related – resolved without sequalae. No procedure-related complications occurred. CONCLUSION: Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington’s disease. Their effects on chorea and dystonia and on quality-of-life should be examined in larger controlled trials. Frontiers Media S.A. 2015-08-18 /pmc/articles/PMC4539552/ /pubmed/26347707 http://dx.doi.org/10.3389/fneur.2015.00177 Text en Copyright © 2015 Wojtecki, Groiss, Ferrea, Elben, Hartmann, Dunnett, Rosser, Saft, Südmeyer, Ohmann, Schnitzler, Vesper and the Surgical Approaches Working Group of the European Huntington’s Disease Network (EHDN). http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Wojtecki, Lars
Groiss, Stefan J.
Ferrea, Stefano
Elben, Saskia
Hartmann, Christian J.
Dunnett, Stephen B.
Rosser, Anne
Saft, Carsten
Südmeyer, Martin
Ohmann, Christian
Schnitzler, Alfons
Vesper, Jan
A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
title A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
title_full A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
title_fullStr A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
title_full_unstemmed A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
title_short A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
title_sort prospective pilot trial for pallidal deep brain stimulation in huntington’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539552/
https://www.ncbi.nlm.nih.gov/pubmed/26347707
http://dx.doi.org/10.3389/fneur.2015.00177
work_keys_str_mv AT wojteckilars aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT groissstefanj aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT ferreastefano aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT elbensaskia aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT hartmannchristianj aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT dunnettstephenb aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT rosseranne aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT saftcarsten aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT sudmeyermartin aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT ohmannchristian aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT schnitzleralfons aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT vesperjan aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT aprospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT wojteckilars prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT groissstefanj prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT ferreastefano prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT elbensaskia prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT hartmannchristianj prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT dunnettstephenb prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT rosseranne prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT saftcarsten prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT sudmeyermartin prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT ohmannchristian prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT schnitzleralfons prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT vesperjan prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease
AT prospectivepilottrialforpallidaldeepbrainstimulationinhuntingtonsdisease